Company intelligence / Profile preview
Citil Pharma
- Ownership
- Private
- Development stage
- Other
01
Overview
Citil Pharma is a biotechnology company developing next-generation in situ CAR-T and NK cell therapies for cancer and autoimmune disease. Its approach is designed to generate or program CAR immune cells in vivo using a combination of nanobody CAR constructs (nanoCAR), tumor-modulating circular RNAs branded as Tmode, and nanobody-targeted lipid nanoparticles. The company states that it is pursuing applications in hematologic malignancies, solid tumors, and autoimmune diseases. Based on publicly available information, Citil Pharma appears to be an early-stage platform biotech focused on cell therapy enabling technologies rather than a disclosed late-stage clinical pipeline.
- Therapeutic areas
- ImmunologyOncology
- Modalities
- CAR-T cell therapyNK cell therapyNanobody therapyRNA therapyLipid nanoparticle delivery therapyBiologic
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Citil Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Citil Pharma.